Despite trial scare, Travere's Filspari gains full FDA nod in kidney disease showdown with Novartis

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. The FDA has converted Filspari’s conditional nod in the kidney disease IgA nephropathy (IgAN) into a full approval.